Novo Nordisk has announced that it's cutting the price of pre-filled insulin pens and vials by up to 75 percent for people living with diabetes starting in January 2024.
"We have been working to develop a sustainable path forward that balances patient affordability, market dynamics, and evolving policy changes," said Steve Albers, senior vice president of market access and public affairs at Novo Nordisk, Inc. "Novo Nordisk remains committed to ensuring patients living with diabetes can afford our insulins, a responsibility we take seriously."
Earlier this month, rival drugmaker Eli Lilly announced plans to reduce insulin prices by 70 percent and cap patient out-of-pocket costs for insulin at $35 per month.
The Biden administration has put public pressure on drugmakers to make medically necessary insulins more affordable. Novo Nordisk notably did not put a cap on out-of-pocket expenses.
Novo Nordisk will lower the price for four different brands, including NovoLog® and NovoLog® Mix 70/30 by 75 percent and Novolin® and Levemir® by 65 percent.
Tobacco manufacturers have started posting new warning signs about cigarettes in over 200,000 stores across the country, one of the final steps in a lawsuit filed by the Justice Department against Big Tobacco in 1999.
The Week's Top Stories is a guided tour through the biggest market stories of the week, from winning stocks to brutal dips to the facts and forecasts generating buzz on Wall Street.
Ahead of the July 4th holiday weekend, flight delays and cancellations have impacted thousands across the country. Cheddar News checked in from New York's LaGuardia Airport for more.
Overstock.com CEO Jonathan Johnson joined Cheddar News after a bankruptcy court approved its purchase of Bed Bath & Beyond's digital and IP assets. Johnson looked ahead to what consumers can expect as those assets are absorbed into Overstock.com and what lies ahead overall.
